Basilea Pharmaceutica
Basilea Pharmaceutica AG, commonly referred to as Basilea, is a Swiss biopharmaceutical company headquartered in Basel, Switzerland. Founded in 2000, Basilea focuses on the development and commercialisation of innovative therapies for oncology and infectious diseases. The company has made significant strides in the pharmaceutical industry, particularly with its core products, which include advanced treatments for resistant infections and cancer. Basilea's unique approach combines cutting-edge research with a commitment to addressing unmet medical needs, positioning it as a key player in the global biopharmaceutical landscape. With a strong presence in Europe and North America, Basilea has achieved notable milestones, including successful product launches and strategic partnerships that enhance its market position. The company's dedication to innovation and patient care continues to drive its growth and reputation in the industry.
DitchCarbon Score
How does Basilea Pharmaceutica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Basilea Pharmaceutica's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Basilea Pharmaceutica's reported carbon emissions
Basilea Pharmaceutica, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As of now, Basilea Pharmaceutica has not inherited any emissions data from a parent or related organization, nor does it have any commitments to the Science Based Targets initiative (SBTi) or other climate initiatives. This lack of data and commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, where sustainability and climate action are increasingly important, Basilea Pharmaceutica may need to establish clear emissions reduction targets and engage in climate initiatives to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Basilea Pharmaceutica is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
